Health-related content. Aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before making decisions. .

INRO: Médicaments, IDE, ESI

INRO: Médicaments, IDE, ESI

By Houari BOUKEROUCHA

INRO is an offline-first clinical assistant for healthcare professionals and nursing students, providing emergency protocols, pharmacology, and clinical scores on iOS and Android.

The App DNA

What makes this app unique?

The application removes the dependency on network connectivity for critical medical data, serving the need for reliable, rapid-access information in high-stress or remote clinical environments.

For Healthcare professionals (doctors, nurses, IADE, SMUR) and nursing students (ESI) in France.

What does it look like?

Key features

Panic Modeedge

One-tap access to critical emergency actions with glove-compatible buttons.

Offline Functionalityedge

Full access to 320 medications and 100+ protocols without network dependency.

ESI Student Areaedge

Technical skills logbook and dosage review for nursing students.

How much does it cost?

freemiumFree base usageINRO Premium (monthly or annual subscription)

The freemium model gates advanced content behind a subscription, while the free tier provides enough utility to maintain a daily open-app habit.

Velocity

Maintenance developmentnew contentperformanceShow more...

With two releases over the last two months, the app operates at a maintenance cadence of approximately one release every 4-5 weeks. Development has shifted between addressing stability issues in the latest version and adding educational content like anatomical diagrams and training modes in the prior release. The current trend is stable, focusing on balancing technical performance with incremental content updates. No further major feature expansion has been observed since the last content-heavy update.

See all version history

Who built it?

Houari BOUKEROUCHA

1 app tracked · Medical

Explore the full publisher profile

User Sentiment

What do users think recently?

Review voice lately leans thrilled. Users appreciate nursing professionals find the anatomical reference content highly valuable for their daily clinical practice requirements.

How are ratings & reviews evolving?

App Store
5.00 · 2
Google Play
0.00 · 0

What users say, by theme

What Users Love
  • Nursing professionals find the anatomical reference content highly valuable for their daily clinical practice requirements
What Frustrates Users
  • Technical instability causing the application to crash upon launch interrupted user access before the latest update

2 of 2 recent reviews analyzed · limited sample

Read the full review analysis

Competition

Competitive landscape for INRO: Médicaments, IDE, ESI

How's the Medical market?

INRO occupies a specialized niche in the French medical category, maintaining a 5.0 rating across two reviews. The current focus on offline-first utility distinguishes the application from general-purpose medical reference tools that require active network connections.

Read the market outlook

The rivals identified

Unlock the deeper market read.

Access the full report for free

The Analyst's Read

Key takeaways for INRO: Médicaments, IDE, ESI

Where is it heading?

The clinical reference market is shifting toward specialized, offline-capable tools that serve specific professional segments like nursing students. INRO is well-positioned to capture this segment if it maintains high reliability, as the current 5.0 rating suggests strong initial product-market fit.

  • The latest release resolved startup crashes, which removes the primary barrier to adoption for new users.
  • Expansion into anatomical training content signals an active feature development cadence that increases the application's daily utility.

The SWOT

Core Strengths
  • Panic Mode's glove-compatible interface provides a defensible barrier in high-stress emergency environments.
  • Offline-first architecture ensures 100% availability in remote or tactical settings.
Critical Frictions 1 weakness inside
Growth Levers
  • Expanding the ESI student area with more procedural kits could capture a larger share of the nursing student market.
Market Threats 1 threat identified

Next best moves

1 Maintain · 1 Invest

Maintain stability and performance because the latest update resolved startup crashes → preserve the current 5.0 rating.

+ 1 more prioritized move

The counter-intuitive read

The subscription model is a risk because professional…

Read the full take

Since the last report: The application's competitive outlook has shifted from a focus on release cadence to a critical evaluation of its subscription model's fit within institutional clinical environments.

Bottom line

INRO's offline-first design and panic-mode utility create a strong foundation for clinical retention, but the transition to a subscription model requires proving consistent reliability to maintain professional trust.

Unlock 1 critical friction, 1 market threat, 1 more prioritized move and the analyst’s take.

Access the full report for free

Sources

  1. [1] App Store, source

Report last updated

Disclosure: Independent intel to help mobile builders succeed.

AI-powered analysis with automated quality gates, built from publicly available sources. Marlvel.ai is not affiliated with, endorsed by, or sponsored by INRO: Médicaments, IDE, ESI, its developer, the app publisher, Apple, or Google Play. All trademarks, logos, and screenshots referenced remain the property of their respective owners.

What's new

The application's competitive outlook has shifted from a focus on release cadence to a critical evaluation of its subscription model's fit within institutional clinical environments.

shifted

Subscription Model Risk Assessment

added

Institutional Adoption Threat

improved

Refined Weakness Definition

shifted

Student Area Opportunity Pivot

Cite this report

Marlvel.ai. “INRO: Médicaments, IDE, ESI Intelligence Report.” Updated Aug 28, 2026. https://marlvel.ai/apps/inro-l-app-des-soignants-ide

Agent Markdown (.md)See methodologyContact support

Data licensed under CC-BY-NC 4.0